ASH to present honorific awards
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
The Immune System's Weirdest Weapon
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
The Super-Soldier Cells Hiding in Your Pus
theatlantic.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theatlantic.com Daily Mail and Mail on Sunday newspapers.
(1)
BEDMINSTER, N.J., Feb. 25, 2021 /PRNewswire/ Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced a collaboration with Boston Children s Hospital (https://wistar.org/) to evaluate peptidyl arginine deiminase 4 (PAD4) inhibitors under development by Jubilant Therapeutics to explore the modulation of neutrophil extracellular traps (NETosis) in preclinical models of neutrophil regulation and rheumatoid arthritis (RA).
PAD4 is an enzyme that converts arginine to citrulline in histones and is highly expressed in neutrophils. Histone citrullination has been implicated in the formation of NETs which is believed to contribute to pro-inflammation and disease progression in many autoimmune disorders including RA, fibrosis, lupus and ARDS.